Trial · NCT05543187
Adverse events64
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 64
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain upper | Gastrointestinal disorders | Primary Cohort: TAK-625 | 0 | 3 | |
| other | Abdominal pain upper | Gastrointestinal disorders | Supplemental Cohort: TAK-625 | 1 | 2 | |
| other | Alanine aminotransferase increased | Investigations | Primary Cohort: TAK-625 | 1 | 3 | |
| other | Alanine aminotransferase increased | Investigations | Supplemental Cohort: TAK-625 | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Primary Cohort: TAK-625 | 1 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Supplemental Cohort: TAK-625 | 0 | 2 | |
| other | Aspartate aminotransferase increased | Investigations | Primary Cohort: TAK-625 | 1 | 3 | |
| other | Aspartate aminotransferase increased | Investigations | Supplemental Cohort: TAK-625 | 0 | 2 | |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Primary Cohort: TAK-625 | 1 | 3 | |
| other | Asthma | Respiratory, thoracic and mediastinal disorders | Supplemental Cohort: TAK-625 | 0 | 2 | |
| other | Auricular haematoma | Injury, poisoning and procedural complications | Primary Cohort: TAK-625 | 0 | 3 | |
| other | Auricular haematoma | Injury, poisoning and procedural complications | Supplemental Cohort: TAK-625 | 1 | 2 | |
| other | Blood bilirubin increased | Investigations | Primary Cohort: TAK-625 | 0 | 3 | |
| other | Blood bilirubin increased | Investigations | Supplemental Cohort: TAK-625 | 1 | 2 | |
| other | COVID-19 | Infections and infestations | Primary Cohort: TAK-625 | 1 | 3 | |
| other | COVID-19 | Infections and infestations | Supplemental Cohort: TAK-625 | 2 | 2 | |
| other | Constipation | Gastrointestinal disorders | Primary Cohort: TAK-625 | 0 | 3 | |
| other | Constipation | Gastrointestinal disorders | Supplemental Cohort: TAK-625 | 1 | 2 | |
| other | Dermatitis | Skin and subcutaneous tissue disorders | Primary Cohort: TAK-625 | 2 | 3 | |
| other | Dermatitis | Skin and subcutaneous tissue disorders | Supplemental Cohort: TAK-625 | 0 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05543187/events